Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cyclacel Pharmaceuticals, Inc.
Xclair Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
July 22nd, 2008
ALIGN Pharmaceuticals, LLC, a wholly owned subsidiary of Cyclacel Pharmaceuticals, Inc., (NASDAQ: CYCC, CYCCP) announced results of a double-blinded, randomized, vehicle-controlled clinical study showing that Xclair(R) cream (formerly MAS065D) is safe and effective in the treatment and prevention of radiation dermatitis. These results were published in the May-June 2008 issue of the European Journal of Dermatology. (1) About the Study Forty women who received radiotherapy following conservative breast cancer surgery were randomized to receive either Xclair cream (22 patients) or a cream containing a control vehicle (18 patients). They received Xclair...
Source: Cancer Weekly (2008-07-22)
|
